hvsa
Home
Courses
Course Objectives
Programs
CME Credits
Cases and Abstract Submissions
venue and accomodations
HVSA
Directors and Faculty
Videos
Register

 

New York City Conference

Back to 2014 Annual Meeting Abstracts


Tricuspid Annuloplasty using the MC3 Ring for Functional Tricuspid Regurgitation: An Analysis of Midterm Outcomes
Yeow Leng Chua,
Philip YK Pang, Mingjie Huang, Noah Tapaua.
National Heart Centre Singapore, Singapore, Singapore.

OBJECTIVE: The aim of this study was to investigate the clinical and echocardiographic outcomes after tricuspid annuloplasty with the 3-dimensional Edwards Lifesciences MC3 ring.
METHODS: A retrospective review was conducted for 120 consecutive patients who underwent tricuspid annuloplasty for functional tricuspid regurgitation (TR) between 2003 and 2013.
RESULTS: Mean age was 60.1 ± 12.1 years with 57.5% females. One hundred and seven patients (89.2%) underwent mitral valve surgery (repair [n=67], replacement [n=40], 10 (8.3%) underwent mitral and aortic valve replacement, 2 (1.7%) underwent repair of atrial septal defect and 1 (0.8%) underwent aortic valve replacement. The indication for tricuspid annuloplasty was severe (4+) or moderately severe (3+) TR in 53 patients (44.2%) and moderate (2+) or less TR with tricuspid annular dilatation in 67 (55.8%). The mean preoperative TR grade was 2.6 ± 1.0 and the mean preoperative pulmonary artery systolic pressure (PASP) was 59.0 ± 21.2 mmHg. The average preoperative tricuspid annulus diameter and implanted MC3 ring size were 33.9 ± 5.5 mm and 26.8 ± 1.4 mm respectively. The mean follow-up period was 4.2 ± 2.9 (0.2 - 10.1) years. Two patients (1.7%) died from multi-organ failure within 30 days of surgery. No patients developed MC3 ring-related complications such as atrioventricular block, ring dehiscence or tricuspid stenosis. Echocardiography after a mean of 3.7 ± 2.6 (0.3 - 9.5) years showed a significant decrease in the average TR grade (2.6 ± 1.0 to 0.7 ± 0.5, P<0.001), PASP (59.0 ± 21.2 vs 32.1 ± 10.2 mmHg, P<0.001) and tricuspid annulus diameter (33.9 ± 5.5 mm vs 26.2 ± 5.1 mm, P<0.001). Overall survival rates were 97.4 ± 1.5%, 91.8 ± 3.1% and 88.0 ± 4.8% at 1, 5 and 8 years respectively. Freedom from recurrent moderate or severe TR was 98.9 ± 1.1% and 95.5 ± 2.6% at 1 and 5 years respectively. Multivariate analysis revealed that recurrent moderate or severe TR was significantly associated with elevated PASP.
CONCLUSIONS: Tricuspid annuloplasty using the MC3 ring corrects functional TR effectively and can be performed with a low incidence of mortality and morbidity, with excellent midterm clinical and echocardiographic results.


Back to 2014 Annual Meeting Abstracts

     

Home | Courses | Objectives | Program | CME Credit | Cases & Abstracts | Venu & Accomodations | HVSA | Committee & Faculty | Register | Privacy Policy